182,618LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
996Accrued liabilities, current5,0933,381Deferred rent, current-453Deferred revenues, current26,78926,789Total current liabilities32,66231,619Non-current liabilities:Accrued liabilities, non-current278-Deferred rent, non-current2,281461Deferred revenues, non-current110,458117,064Total liabilities145,679149,144Stockholders' equity:Common stock2828Additional paid-in capital298,270296,868Accumulated other comprehensive income2721Accumulated deficit(271,405)(263,443)Total stockholders' equity26,92033,474Total liabilities and stockholders' equity$
182,618USE OF NON-GAAP FINANCIAL MEASURESTo supplement the financial statements presented in accordance with generally accepted accounting principles, or GAAP, Vanda uses measures of non-GAAP G&A and R&D expenses. A reconciliation of these non-GAAP financial measures to the closest GAAP financial measure, is presented in the financial table below.
2012 Full Year Guidance GAAP to Non-GAAP adjustmentsFull Year 2012 Guidance(in millions)LowHighGeneral & administrative expenses
5.0G&A Non-cash stock-based compensation
3.03.0Non-GAAP General & administrative expenses
10.012.0Research & development expenses
42.047.0R&D Non-cash stock-based compensation
2.52.5Non-GAAP Research & development expenses
44.5Vanda believes that the non-GAAP financial information provided in this release can assist investors in understanding and assessing the ongoing economics of the company's
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2010 PR Newswire.
All rights reserved